Iota Biosciences, Inc.

Iota Biosciences sits at the intersection of neurotechnology, implantable medical devices, and bioelectronics, with a differentiator that ultrasound—not batteries or wired power—drives power and communication for implantable systems. This places it in a more comparable peer set with ultrasound-based neuromodulation and implantable bioelectronics companies rather than conventional therapeutics-only biotech firms. The company’s competitive framing (bioelectronic devices powered by ultrasound) differentiates it from companies focused on electromagnetics or externally powered implants. Notable competitors/adjacent approaches in the broader space include neural-interface and implantable bioelectronics players such as Synchron (neural interfaces), Blackrock Neurotech (brain data acquisition), and Medtronic’s neuromodulation portfolio—each typically relying on different sensing/drive mechanisms than ultrasound-powered implants. In funding-stage terms, Iota’s last structured round is labeled Series A (Dec 27, 2018) with a reported total raise of ~$15.6M across sources, suggesting early-to-growth scale development rather than late-stage commercial deployment.

Across its publicly available history in the provided data, Iota Biosciences shows a classic early-stage R&D trajectory moving from initial funding to later integration with a major pharma partner. A first financing milestone appears as a Seed round on Nov 15, 2017 for $200K (from Exa), followed by a much larger Series A on Dec 27, 2018 (Crunchbase funding round list and multiple funding-site results) totaling $15,000,001. The dataset also includes a later-stage/VC entry dated Jan 1, 2025 from Exa (“Later Stage VC”) but without an amount, so it cannot be used to quantify a funding inflection. Product and technology development is visible through multiple 2024 patent publications that map to key subsystem challenges: surgical implantation workflows (“Craniectomy cutting template” on Jun 20, 2024) and electrode implantation (“Systems and methods for implanting electrodes in the brain” on Jun 20, 2024), plus implant communications and closed-loop neuromodulation concepts (e.g., “Implantable closed-loop neuromodulation device…” on Jan 16, 2024 and “optimizing communication…” on Feb 29, 2024). The combination of sizable early financing and a sustained 2024 engineering/patent cadence suggests ongoing platform maturation after Series A, with the clearest measurable inflection being the 2018 Series A scale-up.